LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

Phase 3 Completed 839 enrolled Almirall, S.A. Almirall Hermal GmbH · collab Harrison Clinical Research · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis

Timeline

Start: 2012-11
Primary completion: 2014-10
Completion: 2015-11

Publications

Warren RB, Barker JNW, Van de Kerkhof P, Reich K, Mrowietz U. Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e352-e353. doi: 10.1111/jdv.15644. Epub 2019 May 10. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	LASW1835	Unknown	—	—
Subject	dimethyl fumarate	Unknown	—	—

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

Summary

Timeline

Publications

Drugs

Indications